Moderna Inc. said Wednesday that his experimental coronavirus vaccine caused immune responses in people 56 years and older that were comparable to those seen in younger adults in a small study, a promising sign for a vulnerable age group. Older adults have a higher risk of hospitalization and death of …
Read More »
Text size Maddie Meyer / Getty Images Analysts begin to speculate on which of the Covid-19 vaccines could win, after scientists working on two of the most advanced vaccine programs made presentations about their progress at a meeting of a key advisory committee at the Centers for Disease Control and …
Read More »
Text size Dreamstime Older adults who participated in Moderna‘s Phase 1 trial of its Covid-19 vaccine responded just as well as younger adults, according to data, the biotech company presented Wednesday morning to a key Centers for Disease Control and Prevention Advisory panel. This is important because Covid-19 is not …
Read More »
Text size Data from BioNTech and Pfizer were particularly promising. Jeenah Moon / Getty Images After a hiatus from a late summer break, the news of a Covid-19 vaccine is heating up again as a handful of leading programs are rapidly moving to a decisive phase. Reports from several companies …
Read More »
Text size Jeenah Moon / Getty Images Pfizer hopes to get emergency food authorization from the Food and Drug Administration for its Covid-19 vaccine, produced in collaboration with BioNTech, in October – a timeline that is possible, and not the only positive for the biotech industry, according to a Mizuho …
Read More »